Many additional effects in HIV pathogenesis are now described for the chemokine receptor CCR5, long recognized as an important coreceptor for HIV, and its ligand CCL3L1.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Kim Caesar
References
Lederman, M.M., Penn-Nicholson, A., Cho, M. & Mosier, D. J. Am. Med. Assoc. 296, 815–826 (2006).
Murphy, P.M. Fundamental Immunology, 5th edn. (ed. Paul, W.E.) 801–840 (Lippincott Williams and Wilkins, Philadelphia, 2003).
Gonzalez, E., et al. Science 307, 1434–1440 (2005).
Dolan, M.J. et al. Nat. Immunol. 8, 1324–1336 (2007).
Brenchley, J.M. et al. Nat. Med. 12, 1365–1371 (2006).
Deeks, S.G. et al. Blood 104, 942–947 (2004).
Giorgi, J.V. et al. J. Acquir. Immune Defic. Syndr. 6, 904–912 (1993).
Silvestri, G., Paiardini, M., Pandrea, I., Lederman, M.M. & Sodora, D.L. J. Clin. Invest. (in the press).
Pandrea, I. et al. Blood 109, 1069–1076 (2006).
Gonzalez, E. et al. Proc. Natl. Acad. Sci. USA 96, 12004–12009 (1999).
Glass, W.G. et al. J. Exp. Med. 203, 35–40 (2006).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lederman, M., Sieg, S. CCR5 and its ligands: a new axis of evil?. Nat Immunol 8, 1283–1285 (2007). https://doi.org/10.1038/ni1207-1283
Issue Date:
DOI: https://doi.org/10.1038/ni1207-1283
